Prevents mother-to-child transmission of human immunodeficiency virus type-1 (HIV).
Administered as one dose to mother and to newborn reduces transmission of HIV by 41-47%.
Resistance detected in 20-69% of women and 33-87% of infants using genotyping studies after exposure to a single dose of medication in the peripartum period.
Women who received a single dose of drug in the peripartum period to prevent mother-to child transmission of HIV had a significantly higher rate of virologic failure on subsequent antiretroviral treatment with Nevirapine than did women who had received placebo treatment, when such treatment was begun within 6 months of the initial exposure to the drug..